US Patent

US8501698 — Crystal structures of SGLT2 inhibitors and processes for preparing same

Method of Use · Assigned to Bristol Myers Squibb Co · Expires 2027-06-20 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects crystal structures of a compound used in pharmaceutical compositions, including processes for preparing it and methods of treating diseases like diabetes.

USPTO Abstract

The present invention relates to physical crystal structures of a compound of the formula I: wherein R 1 , R 2 , R 2a , R 3 and R 4 are as defined herein, especially pharmaceutical compositions containing structures of compound I or II, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-493 — Farxiga
U-493 — Farxiga
U-2588 —
U-493 — Farxiga
U-493 — Farxiga
U-493 — Farxiga
U-493 — Farxiga
U-493 — Farxiga
U-1976 — Farxiga
U-493 — Farxiga
U-2588 —
U-493 — Farxiga
U-493 — Farxiga
U-493 — Farxiga
U-493 — Farxiga
U-2588 —

Patent Metadata

Patent number
US8501698
Jurisdiction
US
Classification
Method of Use
Expires
2027-06-20
Drug substance claim
No
Drug product claim
Yes
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.